LivaNova PLC宣布，其Aura6000系统已获得美国食品和药物管理局（FDA）的上市前批准，该设备旨在治疗中度至重度的阻塞性睡眠呼吸暂停。这一重要监管里程碑为该公司在美国市场推广其创新疗法铺平了道路。
LivaNova PLC宣布，其Aura6000系统已获得美国食品和药物管理局（FDA）的上市前批准，该设备旨在治疗中度至重度的阻塞性睡眠呼吸暂停。这一重要监管里程碑为该公司在美国市场推广其创新疗法铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.